Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes.
gold nanoparticle
microneedle
peptide immunotherapy
proinsulin
type 1 diabetes
Journal
Immunotherapy advances
ISSN: 2732-4303
Titre abrégé: Immunother Adv
Pays: England
ID NLM: 101776979
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
09
2021
accepted:
24
01
2022
entrez:
3
8
2022
pubmed:
4
8
2022
medline:
4
8
2022
Statut:
epublish
Résumé
Antigen-specific immunotherapy is an immunomodulatory strategy for autoimmune diseases, such as type 1 diabetes, in which patients are treated with autoantigens to promote immune tolerance, stop autoimmune β-cell destruction and prevent permanent dependence on exogenous insulin. In this study, human proinsulin peptide C19-A3 (known for its positive safety profile) was conjugated to ultrasmall gold nanoparticles (GNPs), an attractive drug delivery platform due to the potential anti-inflammatory properties of gold. We hypothesised that microneedle intradermal delivery of C19-A3 GNP may improve peptide pharmacokinetics and induce tolerogenic immunomodulation and proceeded to evaluate its safety and feasibility in a first-in-human trial. Allowing for the limitation of the small number of participants, intradermal administration of C19-A3 GNP appears safe and well tolerated in participants with type 1 diabetes. The associated prolonged skin retention of C19-A3 GNP after intradermal administration offers a number of possibilities to enhance its tolerogenic potential, which should be explored in future studies.
Identifiants
pubmed: 35919496
doi: 10.1093/immadv/ltac002
pii: ltac002
pmc: PMC9327128
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ltac002Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology.
Références
Clin Dev Immunol. 2011;2011:513210
pubmed: 21785617
Immunology. 2015 Nov;146(3):411-22
pubmed: 26293297
Handb Exp Pharmacol. 2009;(188):251-73
pubmed: 19031030
Ann N Y Acad Sci. 2013 May;1284:24-30
pubmed: 23651190
Lancet. 2008 Nov 15;372(9651):1746-55
pubmed: 18814906
Nanomedicine. 2021 Feb;32:102321
pubmed: 33184020
Diabet Med. 2016 Nov;33(11):1564-1568
pubmed: 27425010
Lancet Diabetes Endocrinol. 2019 Jan;7(1):65-74
pubmed: 30528100
Diabetes Care. 2005 May;28(5):1068-76
pubmed: 15855569
Diabet Med. 2013 Feb;30(2):161-9
pubmed: 23231526
Lancet. 2011 Jul 23;378(9788):319-27
pubmed: 21714999
Annu Rev Immunol. 2003;21:685-711
pubmed: 12615891
Diabetes. 2012 Aug;61(8):2066-73
pubmed: 22688329
Sci Adv. 2018 Sep 12;4(9):eaas9930
pubmed: 30221194
Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64
pubmed: 30528099
Dermatitis. 2015 Mar-Apr;26(2):69-77
pubmed: 25757078
Clin Infect Dis. 2021 Jul 15;73(2):e304-e311
pubmed: 32556176
Int J Mol Sci. 2020 Feb 26;21(5):
pubmed: 32111075
JACC Clin Electrophysiol. 2017 Jul;3(7):703-714
pubmed: 28770255
Lancet. 2000 Aug 12;356(9229):545-9
pubmed: 10950231
Diabetes. 2011 Apr;60(4):1237-45
pubmed: 21307076
Vaccine. 2016 Oct 17;34(44):5262-5272
pubmed: 27667332
N Engl J Med. 2008 Oct 30;359(18):1909-20
pubmed: 18843118
Hum Vaccin. 2011 Jan 1;7(1):27-36
pubmed: 21157183
Pharmacol Rep. 2017 Feb;69(1):119-129
pubmed: 27915185
N Engl J Med. 2002 May 30;346(22):1685-91
pubmed: 12037147
Hum Vaccin Immunother. 2015;11(4):991-7
pubmed: 25745830
Diabetes. 2009 Sep;58(9):1939-46
pubmed: 19720821
J Immunol. 2001 Jul 1;167(1):586-92
pubmed: 11418698
Diabetes Care. 2008 Oct;31(10):1966-71
pubmed: 18628574
J Autoimmun. 2010 Jun;34(4):408-15
pubmed: 19931408
Int J Pharm. 2019 May 1;562:303-312
pubmed: 30910633
N Engl J Med. 2012 Feb 2;366(5):433-42
pubmed: 22296077
Nat Rev Immunol. 2008 Dec;8(12):935-47
pubmed: 19029989
Diabetologia. 2020 Oct;63(10):2177-2181
pubmed: 32754804
Diabetes Care. 2009 Aug;32(8):1384-90
pubmed: 19435955
Diabetes Technol Ther. 2019 Feb;21(2):66-72
pubmed: 30657336
Lancet Infect Dis. 2016 Aug;16(8):915-22
pubmed: 27061887
Sci Transl Med. 2017 Aug 9;9(402):
pubmed: 28794283
Clin Exp Immunol. 2013 May;172(2):186-202
pubmed: 23574316
Clin Immunol. 2012 Mar;142(3):332-42
pubmed: 22225835
Clin Exp Immunol. 2009 Feb;155(2):156-65
pubmed: 19040615
Lancet. 2011 Jul 23;378(9788):291-2
pubmed: 21715000
J Am Acad Dermatol. 1994 Oct;31(4):579-83
pubmed: 8089283
J Exp Med. 2012 May 7;209(5):935-45
pubmed: 22547651
Diabetes Care. 2009 Nov;32(11):2036-40
pubmed: 19690081
Lancet. 2019 Oct 5;394(10205):1286-1296
pubmed: 31533907
Histochem J. 1998 Sep;30(9):635-45
pubmed: 9870764